As filed with the Securities and Exchange Commission on December 21, 2022
Registration No. 333-268681
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
HTG Molecular Diagnostics, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 3826 | 86-0912294 | ||
(State or other jurisdiction of incorporation or organization) | (Primary Standard Industrial Classification Code Number) | (I.R.S. Employer Identification Number) |
3430 E. Global Loop
Tucson, AZ 85706
(877) 289-2615
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
John L. Lubniewski
President and Chief Executive Officer
HTG Molecular Diagnostics, Inc.
3430 E. Global Loop
Tucson, AZ 85706
(877) 289-2615
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Steven M. Przesmicki Asa M. Henin Cooley LLP 10265 Science Center Drive San Diego, CA 92121 (858) 550-6000 | Robert F. Charron Ellenoff Grossman & Schole LLP 1345 Avenue of the Americas New York, NY 10105 (212) 370-1300 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering. ☒ 333-268681
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
The Registration Statement shall become effective upon filing in accordance with Rule 462(d) promulgated under the Securities Act of 1933, as amended.
EXPLANATORY NOTE
This Post-Effective Amendment No. 1 (“Amendment No. 1”) to the Registration Statement on Form S-1 (File No. 333-268681), declared effective by the Securities and Exchange Commission on December 21, 2022 (“Registration Statement”), is being filed solely for the purpose of replacing Exhibit 5.1 to the Registration Statement. This Amendment No. 1 does not modify any provision of Part I or Part II of the Registration Statement other than Item 16(a) of Part II as set forth below.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 16. Exhibits and financial statement schedules.
(a) Exhibits.
EXHIBIT INDEX
* | Previously filed. |
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Tucson, Arizona, on the 21st day of December, 2022.
HTG MOLECULAR DIAGNOSTICS, INC. | ||
By: | /s/ John L. Lubniewski | |
John L. Lubniewski | ||
President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Name | Title | Date | ||
/s/ John L. Lubniewski John L. Lubniewski | President, Chief Executive Officer and Director | December 21, 2022 | ||
/s/ Shaun D. McMeans Shaun D. McMeans | Senior Vice President and Chief Financial Officer | December 21, 2022 | ||
/s/ Laura L. Godlewski Laura L. Godlewski | Senior Vice President of Finance Principal Accounting Officer | December 21, 2022 | ||
/s/ Ann F. Hanham* Ann F. Hanham | Chair of the Board of Directors | December 21, 2022 | ||
/s/ Thomas W. Dubensky Jr.* Thomas W. Dubensky Jr., Ph.D. | Director | December 21, 2022 | ||
/s/ Michelle R. Griffin* Michelle R. Griffin | Director | December 21, 2022 | ||
/s/ Christopher P. Kiritsy* Christopher P. Kiritsy | Director | December 21, 2022 | ||
/s/ Donnie M. Hardison* Donnie M. Hardison | Director | December 21, 2022 | ||
/s/ Lee R. McCracken* Lee R. McCracken | Director | December 21, 2022 |
* | Pursuant to power of attorney |
By: | /s/ John L. Lubniewski | |
John L. Lubniewski | ||
Attorney in fact |